This is an auto-generated stub page built from atlas entry frontmatter. A richer
hand-crafted page is planned. See the
atlas source
for the full entry including detailed body sections.
obsessive-compulsive-disorder
Obsessive-Compulsive Disorder
OCD (2-3% lifetime prevalence) is driven by cortico-striato-thalamo-cortical circuit hyperactivity; SSRIs at high doses are first-line; CBT with ERP achieves remission in ~60%; glutamatergic and dopaminergic dysregulation underlie treatment-resistant OCD.
Entry Metadata
| Field | Value |
|---|---|
| ID | obsessive-compulsive-disorder |
| Name | Obsessive-Compulsive Disorder |
| Status | draft |
| Last reviewed | 2026-06-08 |
| Atlas | 01-human |
| Scale | 07-system |
Cross-Atlas Connections
Sources
- Abramowitz JS, Taylor S, McKay D. Obsessive-compulsive disorder. Lancet. 2009;374(9688):491-499. · PubMed 19665647
- Chamberlain SR, Menzies L, Hampshire A, et al. Orbitofrontal dysfunction in patients with obsessive-compulsive disorder and their unaffected relatives. Science. 2008;321(5887):421-422. · PubMed 18635808
- Pittenger C. Glutamate and anxiety disorders. Curr Top Behav Neurosci. 2015;23:145-168. · PubMed 25091538
- Soomro GM, Altman D, Rajagopal S, Oakley-Browne M. Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). Cochrane Database Syst Rev. 2008;(1):CD001765. · PubMed 18253995